18F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer
Recruiting · Phase 4 · NCT06706921
Conditions: Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant, Metastatic Prostate Cancer, Male Urogenital Diseases, Prostatic Diseases, Urogenital Diseases, Male, Genital Diseases, Male, Neoplasms, Neoplasms by Site, Urogenital Neoplasms, Genital Neoplasms, Male
At a glance
- Research payments reported, 2025
- $56,831
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 15
About the trial
- Sponsor
- VA Greater Los Angeles Healthcare System
- Tested
- 18F-Fluciclovine PET/CT Scan (drug)
- Dates
- Started 2024-12-15; completion 2027-11-01
- Results posted
- Not yet
This a single-center, prospective, exploratory study. Patients with metastatic castration-resistant prostate cancer (mCRPC) scheduled to undergo Lutetium labelled prostate-specific membrane antigen radioligand therapy (LuPSMA RLT) at the West Los Angeles VA (WLA-VA) will be imaged with a baseline F-18 fluorodeoxyglucose positron emission tomography/computed tomography 18F-FDG PET/CT and a 18F-DCFPyL PET/CT (18F-DCFPyL (2-(3-{1-carboxy-5-\[(6-18F-fluoro-pyridine-3-carbonyl)-amino\]-pentyl}-ureido)-pentanedioic acid)positron emission tomography/computed tomography , as per standard of care in our institution. All patients further undergo eventual follow-up prostate-specific membrane antigen…
From ClinicalTrials.gov, last updated 2024-11-27. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Blue Earth Diagnostics reported $56,831 in research payments for this study in 2025 (11 payments).
Products named: Axumin
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- VA Greater Los Angeles Healthcare $56,831
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.